SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database

OBJECTIVES: To estimate the health care resource use (HCRU) and costs for patients diagnosed with acromegaly, following treatment with either pegvisomant, a growth hormone receptor antagonist (GHRA); or a somatostatin analogue (SSA). METHODS: De-identified data from Optum’s Clinformatics(TM) Data Ma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Kelepouris, Nicky, Emir, Birol, Loftus, Jane, Rubinstein, Emily, King, Donna, McDonald, Margaret
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Neuroendocrinology and Pituitary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551765/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-439
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados